EGFR and non-small cell lung carcinoma: Another key trial investigating these dual-target approaches is the multi-arm phase Ib TATTON study, which is evaluating osimertinib in combination with savolitinib, selumetinib (MEK1/2 inhibitor), and durvalumab (anti-PD-L1 antibody) in T790M-positive EGFR-mutant NSCLC [305,306].